|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NONO |
Gene summary for NONO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NONO | Gene ID | 4841 |
| Gene name | non-POU domain containing octamer binding | |
| Gene Alias | MRXS34 | |
| Cytomap | Xq13.1 | |
| Gene Type | protein-coding | GO ID | GO:0002218 | UniProtAcc | A0A0S2Z4Z9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4841 | NONO | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.23e-13 | 4.33e-01 | 0.0155 |
| 4841 | NONO | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.46e-03 | 4.21e-01 | -0.1808 |
| 4841 | NONO | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.35e-06 | 6.96e-01 | 0.0216 |
| 4841 | NONO | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.14e-12 | 7.21e-01 | -0.0811 |
| 4841 | NONO | HTA11_78_2000001011 | Human | Colorectum | AD | 1.23e-15 | 5.48e-01 | -0.1088 |
| 4841 | NONO | HTA11_347_2000001011 | Human | Colorectum | AD | 1.65e-21 | 7.20e-01 | -0.1954 |
| 4841 | NONO | HTA11_411_2000001011 | Human | Colorectum | SER | 2.90e-02 | 7.13e-01 | -0.2602 |
| 4841 | NONO | HTA11_83_2000001011 | Human | Colorectum | SER | 1.13e-02 | 2.55e-01 | -0.1526 |
| 4841 | NONO | HTA11_696_2000001011 | Human | Colorectum | AD | 1.05e-15 | 5.04e-01 | -0.1464 |
| 4841 | NONO | HTA11_866_2000001011 | Human | Colorectum | AD | 3.72e-06 | 3.65e-01 | -0.1001 |
| 4841 | NONO | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.04e-24 | 9.97e-01 | -0.059 |
| 4841 | NONO | HTA11_546_2000001011 | Human | Colorectum | AD | 5.56e-10 | 6.28e-01 | -0.0842 |
| 4841 | NONO | HTA11_7862_2000001011 | Human | Colorectum | AD | 9.41e-12 | 7.72e-01 | -0.0179 |
| 4841 | NONO | HTA11_866_3004761011 | Human | Colorectum | AD | 3.85e-39 | 1.18e+00 | 0.096 |
| 4841 | NONO | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.21e-07 | 7.89e-01 | 0.0446 |
| 4841 | NONO | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.25e-11 | 9.43e-01 | 0.0528 |
| 4841 | NONO | HTA11_7663_2000001011 | Human | Colorectum | SER | 9.88e-12 | 9.21e-01 | 0.0131 |
| 4841 | NONO | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.22e-08 | 7.20e-01 | -0.0177 |
| 4841 | NONO | HTA11_6801_2000001011 | Human | Colorectum | SER | 3.65e-14 | 1.17e+00 | 0.0171 |
| 4841 | NONO | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.80e-07 | 5.53e-01 | 0.0338 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000762321 | Liver | HCC | circadian rhythm | 117/7958 | 210/18723 | 7.29e-05 | 6.54e-04 | 117 |
| GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
| GO:000863112 | Liver | HCC | intrinsic apoptotic signaling pathway in response to oxidative stress | 32/7958 | 45/18723 | 9.63e-05 | 8.34e-04 | 32 |
| GO:004352312 | Liver | HCC | regulation of neuron apoptotic process | 117/7958 | 212/18723 | 1.25e-04 | 1.03e-03 | 117 |
| GO:190217512 | Liver | HCC | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 22/7958 | 29/18723 | 2.73e-04 | 1.98e-03 | 22 |
| GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
| GO:190121512 | Liver | HCC | negative regulation of neuron death | 113/7958 | 208/18723 | 3.68e-04 | 2.54e-03 | 113 |
| GO:003647511 | Liver | HCC | neuron death in response to oxidative stress | 22/7958 | 31/18723 | 1.27e-03 | 6.92e-03 | 22 |
| GO:003647312 | Liver | HCC | cell death in response to oxidative stress | 55/7958 | 95/18723 | 1.76e-03 | 9.12e-03 | 55 |
| GO:00450881 | Liver | HCC | regulation of innate immune response | 113/7958 | 218/18723 | 3.27e-03 | 1.50e-02 | 113 |
| GO:190217612 | Liver | HCC | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 15/7958 | 20/18723 | 3.31e-03 | 1.51e-02 | 15 |
| GO:0002218 | Liver | HCC | activation of innate immune response | 32/7958 | 52/18723 | 4.35e-03 | 1.89e-02 | 32 |
| GO:190288212 | Liver | HCC | regulation of response to oxidative stress | 55/7958 | 98/18723 | 4.46e-03 | 1.93e-02 | 55 |
| GO:190040712 | Liver | HCC | regulation of cellular response to oxidative stress | 50/7958 | 89/18723 | 6.33e-03 | 2.58e-02 | 50 |
| GO:004275211 | Liver | HCC | regulation of circadian rhythm | 65/7958 | 121/18723 | 8.25e-03 | 3.24e-02 | 65 |
| GO:190320112 | Liver | HCC | regulation of oxidative stress-induced cell death | 42/7958 | 74/18723 | 9.32e-03 | 3.57e-02 | 42 |
| GO:190320311 | Liver | HCC | regulation of oxidative stress-induced neuron death | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
| GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| NONO | STM | Liver | Cirrhotic | MFSD9,HNRNPU,LCMT1, etc. | 4.68e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NONO | SNV | Missense_Mutation | c.292N>A | p.Gly98Arg | p.G98R | Q15233 | protein_coding | deleterious(0.01) | possibly_damaging(0.768) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| NONO | SNV | Missense_Mutation | c.911N>A | p.Arg304His | p.R304H | Q15233 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
| NONO | SNV | Missense_Mutation | novel | c.1081G>A | p.Glu361Lys | p.E361K | Q15233 | protein_coding | deleterious(0) | possibly_damaging(0.587) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| NONO | insertion | Frame_Shift_Ins | novel | c.853_854insA | p.Val285AspfsTer10 | p.V285Dfs*10 | Q15233 | protein_coding | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
| NONO | insertion | In_Frame_Ins | novel | c.854_855insCTC | p.Val285_Asp286insSer | p.V285_D286insS | Q15233 | protein_coding | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
| NONO | insertion | Frame_Shift_Ins | novel | c.1405_1406insACTTTAAGGGGGTGACATATATGTCTTACTTA | p.Arg469HisfsTer26 | p.R469Hfs*26 | Q15233 | protein_coding | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| NONO | deletion | Frame_Shift_Del | c.1268delG | p.Gly423GlufsTer5 | p.G423Efs*5 | Q15233 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| NONO | SNV | Missense_Mutation | novel | c.523N>C | p.Glu175Gln | p.E175Q | Q15233 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| NONO | SNV | Missense_Mutation | novel | c.265N>A | p.Glu89Lys | p.E89K | Q15233 | protein_coding | deleterious(0) | benign(0.021) | TCGA-EX-A8YF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| NONO | SNV | Missense_Mutation | c.694N>C | p.Asp232His | p.D232H | Q15233 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |